Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CeMines takes lung cancer diagnostic:

This article was originally published in Clinica

Executive Summary

CeMines has CE-marked for sale in Europe its molecular blood test kit for helping doctors diagnose lung cancer. The CellCorrect KvA-40 LAb kit, the first product from the firm's CellCorrect family of tests to reach the market, is accurate, simple-to-use and cost-effective, claims the Golden, Colorado-based company. It detects disease-related antibodies in the blood using CeMines' Molecular FingerPrinting bioinformatics technology, which evaluates cancer-related antibody patterns and their relevant statistical profiles; the test is able to differentiate and characterise the cancer. Its data are presented in an easy-to-read "score format" that does not require subjective interpretation by physicians. In the US, CeMines filed a 510(k) marketing application for the test in May last year.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT050642

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel